Transdermal and topical pharmacotherapy for male sexual dysfunction

Expert Opinion on Drug Delivery

Volumn 2, Issue 1, 2005, Pages 115-120

  Ohebshalom, Michael ^b   Mulhall, John P ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Erectile dysfunction; Hypogonadism; Iontophoresis; Peyronie's disease; Testosterone; Transdermal

Indexed keywords

4 AMINOBENZOATE POTASSIUM; AGENTS ACTING ON THE GENITAL SYSTEM; ALPHA TOCOPHEROL; COLCHICINE; COLLAGENASE; CORTICOSTEROID; DEXAMETHASONE; GLYCERYL TRINITRATE; INTERFERON; NEXACT; NITRIC OXIDE SYNTHASE; PAPAVERINE; PLACEBO; PROSTAGLANDIN E1; TAMOXIFEN; TESTOSTERONE; VERAPAMIL;

BITTER TASTE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG WITHDRAWAL; EDEMA; ENZYME ACTIVITY; ERECTILE DYSFUNCTION; ERYTHEMA; GEL; GINGIVA DISEASE; HEADACHE; HUMAN; HYPOGONADISM; IONTOPHORESIS; MALE; MALE SEXUAL DYSFUNCTION; MEDLINE; MOUTH DISEASE; NONHUMAN; PENIS ERECTION; PEYRONIE DISEASE; REVIEW; SKIN BURNING SENSATION; SKIN IRRITATION; SKIN MANIFESTATION; SYSTEMATIC REVIEW; TASTE DISORDER; TESTOSTERONE BLOOD LEVEL; TRANSDERMAL PATCH;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, TOPICAL; ALPROSTADIL; ANDROGENS; ANIMALS; HUMANS; HYPOGONADISM; IMPOTENCE; IONTOPHORESIS; MALE; MEDLINE; PAPAVERINE; PENILE INDURATION; PHARMACEUTICAL PREPARATIONS; PHOSPHODIESTERASE INHIBITORS; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TESTOSTERONE; URETHRA; VASODILATOR AGENTS; VERAPAMIL;

EID: 12344318175     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.2.1.115     Document Type: Review

References (35)

1. SALASHE SJ, BERNSTEIN G, SENKARIK MS: Surgical anatomy ofthe skin. McGraw Hill (1988):241.
2. FREINKEL R, WOODBY D: The Biology of the skin. Parthenon Publishing (2001):162.
3. BOUWSTRA JA, HONEYWELL-NGUYEN PL: Skin structure and mode of action of vesicles. Adv. Drug Deliv. Rev. (2002) 54(Suppl. 1):S41-S55.
4. MORALES A: Developmental status of topical therapies for erectile and ejaculatory function. Int. J. Imp. Res. (2000) 12 Suppl. 4):S80-S85.
5. PRYOR JL, REDMAN B: New therapies and delivery mechanisms for treatment of erectile dysfunction. Int. J. Imp. Res. (2000) 12 S158.
6. NIH Consensus Developmental Panel on Impotence. JAMA (1993) 270:83.
7. Gray's Anatomy of the Human Body, 30th edition ed.
8. ABOSEIF SR, LUE TF: Fundamentals and hemodynamics of penile erection. Cardiovasc. Intervent. Radiol. (1988) 11 4):185-190.
9. RAJFER J, ARONSON WJ, BUSH PA, DOREY FJ, IGNARRO LJ: Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to noradrenergic, noncholinergic transmission. N. Engl. J. Med. (1992) 326(2):90-94.
10. OWEN JA SAUNDERS F, HARRIS C et al.: Topical nitroglycerin: a potential treatment for impotence. J. Urol. (1989) 141(3):546-548.
11. KIM ED, ELRASHIDY R, MCVARY KT: Papaverine topical gel for treatment of erectile dysfunction. J. Urol. (1995) 153 2):361-365.
12. GOLDSTEIN I, PAYTON TR, SCHECHTER PJ: A double-blind, placebo-controlled, efficacy and safety study of topical gel formulation of 1% alprostadil (Topiglan) for the office treatment of erectile dysfunction. Urology (2001) 57(2):301-305.
13. PADMA-NATHAN H, STEIDLE C, SALEM S, TAYSE N, YEAGER J, HARNING R: The efficacy and sakty of a topical alprostadil cream, Alprox-TD, for the treatment of erectile dysfunction: two Phase II studies in mild-to-moderate and severe ED. Int. J. Impot. Res. (2003) 15(1):10-17.
14. HELLSTROM WJ, BIVALACQUA TJ: Peyronie's disease: etiology, medical, and surgical therapy. J. Androl. (2000) 21 3):347-354.
15. ANDERSON MS, SHANKEY TV, LUBRANO T, MULHALL JP: In-vitro inhibition of peyronie's plaque fibroblast proliferation by biologic agents. Int. J. Impot. Res. (2000) 12(Suppl. 3):S25-S31.
16. FITCH W, EASTERLING WJ: Topical verapamil, trifluoroperazine, and magnesium sulafate for peyronie's disease. Int. J. Impot. Res. (2001) 13:S62.
17. MARTIN DJ, BADWAN R, PARKER M, MULHALL J: Transdermal application of verapamil gel to penile shaft fails to infiltrate tunica albuginea. J. Urol. (2002) 168(6):2483-2485.
18. RIEDL CR, PLAS E, ENGELHARDT P, DAHA K, PFLUGER H: Iontophoresis for treatment of Peyronie's disease. J. Urol. (2000) 163(1):95-99.
19. MILLS TM, REILLY CM, LEWIS R.W: Androgens and penile erection: a review. J. Androl. (1996) 17(6):633-638.
20. SHABSIGH R: The effects of testosterone on the cavernous tissue and erectile function. World J. Urol. (1997) 15 1):21-26.
21. PARK K, KIM SW, KIM KD, PAICK L: Effects of androgens on the expression of nitric oxide synthase in mRNAs in rat corpus cavernosum. BJU Int. (1999) 83(3):327-333.
22. PIERCE JG, PARSONS TF: Glycoprotein hormones structure and function. A. Rev. Biochem. (1981) 50:465-495.
23. WOLLESSEN F, SWERDLOFF RS, ODELL WD: LH and FSH responses to luteinizing releasing hormones in normal adult human males. Metabolism (1976) 25(11):1275-1285.
24. LUGG JA, RAJFER J, GONZALEZ-CADAVID NF: Dihydrotestosterone is the active androgen in the maintenance of nitric-oxide mediated penile erection in the rat. Endocrinology (1995) 136(4): 1495-1501.
25. MARIN R, ESCRIG A, ABREU P, MAS M: Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. Biol. Reprod. (1999) 61 4):1012-1016.
26. ZHANG XH, HU LQ, ZHENG XM, LI SW: Apoptosis in rat erectile tissue induced by castration. Asian J. Androl. (1999) 1 4):181-185.
27. DAI YT, STOPPER V, LEWIS R, MILLS T: Effects of castration and testosterone replacement on veno-occlusion during penile erection in the rat. Asian J. Androl. (1999) 1(1-2):53-59.
28. BANCROFT J: Hormones and human sexual behavior. J. Sex Marital Ther. (1984) 10(1):3-21.
29. AHMED SR, BOUCHER AE, MANNI A: Transdermal testosterone therapy in the treatment of male hypogonadism. J Clin. Endecrinol. Metab. (1988) 66(3):546-551.
30. MCCLURE RD, OSES R, ERNEST ML: Hypogonadal impotence treated by transdermal testosterone. Urology (1991) 37(3):224-228.
31. MEIKLE AW, MAZER NA, MOELLMER JF: Enhanced transdermal delivery of testosterone across nonscrotal skin produces physiological concentrations of testosterone and its metabolites in hypogonadal men. J. Clin. Endocrinol. Metab. (1992) 74(3):623-628.
32. ARVER S, DOBS AS, MEIKLE AE: Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin. Endocrinol. (1997) 47(6):727-737.
33. WANG C, SWEDLOFF R, KIPNESS M et al.: New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmakokinetics study in hypogonadal men. J. Clin. Endocrinol. Metab. (2004) 89(8):3821-3829.
34. STEIDLE C, SCHWARTZ S, JACOBY K, SEBREE T, SMITH T, BACHAND R; NORTH AMERICAN AA2500 T GEL STUDY GROUP: AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. (2003) 88(6):2673-2681.
35. KORBONITS M, SLAWIK M, CULLEN D et al.: A comparison of a novel testosterone bioadhesive buccal system, Striant, with a testosterone adhesive patch in hypogonadal males. J. Clin. Endocrinol. Metab. (2004) 89(5):2039-2043.